Vir Biotechnology EBIT

The latest EBIT for VIR is $-200M as of September 2026. That compares with $-550M in the prior-year period — up 64.2% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Vir Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, VIR's EBIT moved from $-550M to $-200M — a 64.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Vir Biotechnology's operating scale or balance-sheet position.

Against Healthcare companies, VIR currently prints $-200M for EBIT, while the sector average sits near $99B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Vir Biotechnology's growth, margins, and balance sheet.

A EBIT figure of $-200M for VIR is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting VIR's EBIT ($-200M), review year-over-year change from $-550M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.